Fig. 2From: Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomasThe prognostic performance of the RISK score signature in different validation cohorts of non-G-CIMP GBMs, a Patient classification in validation cohorts with the combination of RT and TMZ, b Patient classification in validation cohorts with RT alone. GBM glioblastoma, G-CIMP glioma-CpGs island methylator phenotype, RT radiotherapy, TMZ temozolomideBack to article page